In the BioHarmony Drug Report Database

"Preview" Icon

Pregabalin

Lyrica (pregabalin) is a small molecule pharmaceutical. Pregabalin was first approved as Lyrica on 2004-07-05. It is used to treat fibromyalgia, postherpetic neuralgia, seizures, and spinal cord injuries in the USA. It has been approved in Europe to treat anxiety disorders, epilepsy, and neuralgia. The pharmaceutical is active against voltage-dependent calcium channel subunit alpha-2/delta-1. In addition, it is known to target voltage-dependent calcium channel subunit alpha-2/delta-2. Lyrica’s patent is valid until 2026-11-02 (FDA).

 

Trade Name

 

Lyrica
 

Common Name

 

pregabalin
 

ChEMBL ID

 

CHEMBL1059
 

Indication

 

anxiety disorders, epilepsy, fibromyalgia, neuralgia, postherpetic neuralgia, seizures, spinal cord injuries
 

Drug Class

 

Gabamimetics

Image (chem structure or protein)

Pregabalin structure rendering